Evidence map›Paper›PMID 42655729›Full record

ReviewViruses2026

Molecular Insights into High-Pathogenicity RNA Viruses.

Hana Krnjić, Adna Hrapović, Aiša Galijatović, Ajla Tipura, Maida Hajdarpašić, Selma Kozarić, Adna Berilo, Naida Odobašić, Altijana Hromić-Jahjefendić, Jasmin Šutković

Abstract readReview
In one paragraph

Review in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hana KrnjićGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.ORCID 0009-0000-8600-4755
Adna HrapovićGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.ORCID 0009-0002-0654-3068
Aiša GalijatovićGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.
Ajla TipuraGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.
Maida HajdarpašićGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.
Selma KozarićGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.
Adna BeriloGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.ORCID 0009-0008-9724-8681
Naida OdobašićGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.ORCID 0009-0005-2873-6006
Altijana Hromić-JahjefendićGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.
Jasmin ŠutkovićGenetics and Bioengineering, Faculty of Engineering and Natural Sciences, International University of Sarajevo, Ilidža, 71000 Sarajevo, Bosnia and Herzegovina.ORCID 0000-0001-9962-6908

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Highly pathogenic RNA viruses, such as Ebola, SARS-CoV-2, and influenza, cause severe disease in humans. High mutation rates, which enable RNA viruses to evade immunity and escape antivirals, and their ability to spread from animals to humans and cause pandemics and outbreaks, make RNA viruses significant threats to public health. Diseases caused by Ebola, SARS-CoV-2, and influenza are prevented and treated with only a limited number of approved antiviral drugs, the effectiveness of which is limited by mutations in the viral targets. It is crucial to understand the structural determinants, molecular mechanisms, and host interactions of pathogenic RNA viruses to develop effective antiviral strategies. In this review, we discuss selected RNA viruses, focusing on the structure of their RNA polymerases and interactions with host factors during the different stages of the viral lifecycle, as well as the traditional antivirals targeting these structures and pathways. Furthermore, emerging concepts such as liquid-liquid phase separation and biomolecular condensates, and novel promising antiviral strategies are discussed. Understanding shared and distinct structures, molecular mechanisms, and host interactions across highly pathogenic RNA viruses enables the discovery of new and more effective antiviral strategies, ultimately improving clinical outcomes against evolving RNA viruses.

Indexed as

RNA VirusesRNA Virus InfectionsAnimalsAntiviral AgentsDNA-Directed RNA PolymerasesHost-Pathogen InteractionsHumansRNA ReplicationSARS-CoV-2Viral ProteinsVirus ReplicationAntiviral AgentsDNA-Directed RNA PolymerasesViral Proteinsantiviral targetsbiomolecular condensatesEbola virushost–virus interactionsInfluenza A virusliquid–liquid phase separationRNA virusesSARS-CoV-2

Identifiers

PMID42655729
PMCPMC13517795

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.